



IFW

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	<b>10/809,068</b>
	Filing Date	<b>March 25, 2004</b>
	First Named Inventor	<b>Mutel et al.</b>
	Art Unit	<b>1625</b>
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	<b>20856 US2</b>

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks  <b>PTO-1449 Form</b>	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	<b>Kimberly J. Prior</b>
Signature	
Date	<b>June 25, 2004</b>

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	<b>Kimberly J. Prior</b>		
Signature		Date	<b>June 25, 2004</b>

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventors: Mutel, et al.

Group: 1625

Serial No. 10/809,068, filed March 25, 2004  
(Ref. No. 20856 US2)

Examiner: Aulakh, C.

For: SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES

**INFORMATION DISCLOSURE STATEMENT**

Nutley, New Jersey 07110  
June 25, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents A1, A2, B1 to B18, and C1 to C19 are listed on Form PTO-1449.


None of the documents listed on Form PTO 1449 are being submitted because each document has been made of record in the parent application, Serial No. 10/407,928, filed April 4, 2003, now pending.

Serial No. 10/809,068  
Filed: March 25, 2004

Consideration of all the documents cited on Form PTO-1449 is requested.


Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,

  
Attorney for Applicant(s)  
Kimberly J. Prior  
(Reg. No. 41,483)  
340 Kingsland Street  
Nutley, New Jersey 07110  
Telephone: (973) 235-6208  
Telefax: (973) 235-2363

Enclosure

143319



Substitute for form 1449A/PTO				Complete if Known			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)				Application Number	10/809,068		
				Filing Date	March 25, 2004		
				First Name Inventor	Mutel, et al.		
				Group Art Unit	1625		
				Examiner Name	Aulakh, C.		
Sheet	1	of	2	Attorney Docket Number	20856 US2		
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY		
		Number	Kind Code <sup>2</sup> (if known)				
	A1	3,701,780		Merck & Co., Inc.	10/31/1972		
	A2	6,596,731		Mutel, et al.	07/2003		
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
	B1	CH	590 862		Ciba Geigy AG	08/31/1977	
	B2	EP	050 563		Synthelabo	04/28/1982	
	B3	EP	092 458		Synthelabo	10/26/1983	
	B4	EP	092 459		Synthelabo	10/26/1983	
	B5	EP	172 096		Synthelabo	02/19/1986	
	B6	EP	185 345		Dr. Karl Thomae GmbH	06/25/1986	
	B7	EP	234 970		Synthelabo	09/02/1987	
	B8	EP	251 859		Synthelabo	01/07/1988	
	B9	EP	267 111		Synthelabo	05/11/1988	
	B10	FR	2 581 646		Synthelabo	11/14/1986	
	B11	JP	11-116481		Sumitomo Seiyaku KK	04/27/1999	
	B12	JP	50-140477		Yoshitomi Pharm Ind KK	11/11/1975	
	B13	JP	51-004194		Yoshitomi Pharm Ind KK	01/14/1976	
	B14	JP	51-125095		Yoshitomi Pharm Ind KK	11/01/1976	
	B15	WO	98/39342		Metabasis Therapeutics, Inc.	09/11/1998	
	B16	WO	00/08021		Quimica Sintetica, S.A.	02/17/2000	
	B17	WO	01/74815		Ortho McNeil	10/11/2001	
	B18	WO	91/19497		SmithKline Beecham Corp.	12/26/1991	
Examiner Signature		Date Considered					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation or abstract is attached.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)				Application Number	10/809,068
				Filing Date	March 25, 2004
				First Name Inventor	Mutel, et al.
				Group Art Unit	1625
				Examiner Name	Aulakh, C.
Sheet	2	of	2	Attorney Docket Number	20856 US2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	C1	SCHLAEGER et al., Cytotechnology, 30, pgs. 71-83 (1999)	
	C2	MÖHLER et al., Nature, 294, pgs. 763-765 (1981)	
	C3	KATRITZKY et al., J. Org. Chem., 65, pgs. 9201-9205 (2000)	
	C4	SUNDBER et al., J. Heterocyclic Chem., 25, pgs. 129-137 (1988)	
	C5	ANDREANI et al., Eur. J. Med. Chem., 29, pgs. 339-342 (1994)	
	C6	HABERMANN et al., J. Chem. Soc., Perkin Trans. 1, pgs. 2425-2427 (1999)	
	C7	ARBILLA et al., Eur. J. Pharmacol., 130, pgs. 257-263 (1986)	
	C8	MARUYAMA et al., Arzneim.-Forsch, 31(7), pgs. 1111-1118 (1981)	
	C9	CRESTANI et al., Br. J. Pharmacol, 131, pgs. 1251-1254 (2000)	
	C10	BUU-HOÏ et al., J. Org. Chem., 19, pgs. 1370-1374 (1954)	
	C11	BUU-HOÏ et al., Recl. Trav. Chim. Pays-Bas, 68, pgs. 441-472 (1949)	
	C12	MÖHLER et al., J. Neurochemistry, 37, pgs. 714-722 (1981)	
	C13	TOMODA et al., Bull. Chem. Soc. Jpn., 72, pgs. 1327-1334 (1999)	
	C14	LOISEAU et al., Eur. J. Med. Chem, 22, pgs. 457-462 (1987)	
	C15	KEMPTER et al., J. Prakt. Chem, 313, pgs. 977-985 (1971)	
	C16	PENTIMALLI et al., Boll. Sci. Fac. Chim. Ind. Bologna, 24, pgs. 205-214 (1966)	
	C17	KHIM-FARM Zh., 4, pgs. 20-26 (1970)	
	C18	BARLIN, Gordon B., Journal of Heterocyclic Chemistry, 35(5), pgs. 1205-1217 (1998)	
	C19	ALMIRANTE, Luigi et al., J. Med. Chem., 8(3), pgs. 305-312 (1965)	
Examiner Signature			DATE CONSIDERED

<sup>2</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation or abstract is attached.

143261